Two siblings with Schaaf-Yang syndrome treated with growth hormone

Read full text
Authors: Yukiko Hashimoto, Kazutaka Nanba, Yosuke Konishi, Takashi Matsukura, Naoko Yano, Takeshi Yoshida
Cited by: 1
References: 13

Abstract

Schaaf-Yang syndrome (SYS) is a rare neurodevelopmental disorder with overlapping features with Prader-Willi syndrome (PWS). We report two Japanese siblings with SYS harboring a rare MAGEL2 variant (NM_019066.5:c.1621C>T, p.(Q541*)). Both patients had growth hormone (GH) deficiency and received GH therapy. The older sibling presented with neonatal hypotonia, joint contractures, and severe autism, while the younger sibling showed milder features but developed obesity and behavioral problems. GH therapy led to only modest improvement in their growth. The limited effect may have been related to the late initiation of treatment, marked non-adherence to therapy, and GH doses. This report highlights the phenotypic variability of SYS and demonstrates difficulties and potential issues of GH treatment as well as clinical response to GH treatment in this rare disorder.

Fields of Study & Subjects

Genetic Syndromes and Imprinting Connective tissue disorders research Neurogenetic and Muscular Disorders Research

Publication details

Journal / source
Clinical Pediatric Endocrinology
Publisher
Japanese Society for Pediatric Endocrinology
Volume
35
Issue
2
Pages
186–191
Publication date
1 January 2026
Language
EN